Denosumab (Xgeva) injection

Denosumab (Xgeva) J0897 is covered for prevention of skeletal‑related events from bone metastases of solid tumors, treatment of unresectable or high‑morbidity giant cell tumor of bone in adults/skeletally mature adolescents, hypercalcemia of malignancy refractory to IV bisphosphonates, and specified compendial off‑label uses (certain breast and castration‑recurrent prostate cancer indications and fracture‑prevention in high‑risk postmenopausal breast cancer); it is not covered for multiple myeloma or other hematologic (nonsolid) tumors. Coverage requires documentation of diagnosis and indication‑specific criteria (e.g., expected survival ≥3 months for metastatic breast cancer, castration‑recurrent disease for prostate cancer, prior IV bisphosphonate failure for hypercalcemia, BMD/FRAX or fracture history for fracture‑prevention), safety checks (serum calcium above lab lower limit, pregnancy excluded for women of childbearing potential), calcium/vitamin D supplementation and dental evaluation/monitoring as appropriate, and is approved for up to 12 months with caution in severe renal dysfunction.